TD Cowen initiates coverage on Mirum Pharmaceuticals stock with Buy rating
PositiveFinancial Markets

TD Cowen has started coverage on Mirum Pharmaceuticals, giving it a 'Buy' rating. This is significant as it reflects confidence in Mirum's potential for growth and success in the pharmaceutical market, which could attract more investors and boost the company's stock performance.
— Curated by the World Pulse Now AI Editorial System